Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors

Research output: Contribution to journalLetterOtherpeer-review

14 Citations (Scopus)


We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID-19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID-19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID-19.[2].

Original languageEnglish
Pages (from-to)569-570
Number of pages2
JournalAlimentary Pharmacology & Therapeutics
Issue number3
Publication statusPublished - Aug 2020

Cite this